米非司酮保守性治疗围绝经期子宫肌瘤的疗效及影响因素

doi:10.3969/j.issn.1671-7171.2017.06.010

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical effect of mifepristone in the treatment of uterine fibroids and its influencing factors. 【Methods】 Forty patients with myoma of uterus treated in our hospital from December 2010 to June 2016 were selected; Mifepristone was used to compare the volume change of hysteromyoma before and after treatment, and the factors influencing the effect of mifepristone treatment were analyzed.【Results】 The volume of myoma of uterus decreased significantly after treatment (P<0.05); The effect of mifepristone was poor in patients with myoma of uterus larger than 3 cm, ER receptor negative, uterine fibroids >6 months and the fibroids located under the serosa(P<0.05). 【Conclusion】 Mifepristone is effective in the treatment of uterine fibroids; ER receptor, myoma size and course of disease are the main factors that influence the effect of mifepristone treatment.

Key words： Uterine Neoplasms/DT Leiomyoma/DT Perimenopause Mifepristone/TU Risk Factors

Received: 23 January 2017

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Dong-hong

Cite this article:

YANG Dong-hong. Clinical Effect and Influencing Factors of Mifepristone in the Conservative Treatment of Peri Menopausal Uterine Fibroids[J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(6): 1075-1077.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.06.010 OR http://www.jcr.net.cn/EN/Y2017/V34/I6/1075

[1] 贾卫静,江金. 米非司酮独用及与宫瘤消胶囊合用治疗子宫肌瘤的效果评价[J].中国生化药物杂志,2014,7(4):111-112.
[2] 李岩,曲亚兰,李丹阳,等. 米非司酮预防子宫肌瘤患者术后复发的疗效观察[J].医学临床研究,2015,32(3):499-500.
[3] Engman M, Varghese S, Lagerstedt Robinson K,et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment[J].PLoS One,2013,8(12):e80114.
[4] Kulshrestha V, Kriplani A, Agarwal N, et al. Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India[J].Indian J Med Res,2013,137(6):1154.
[5] 魏俊秀,杨欣,李晓冬. 米非司酮治疗子宫肌瘤的再认识[J].中国妇产科临床杂志,2016(06):561-562.
[6] 杨柳,何顺之,黄晓燕. 米非司酮对减少子宫肌瘤术后再复发的探讨[J].重庆医学,2014,43(17):2209-2211.
[7] 方海娅,张海燕,寿华锋. 米非司酮治疗围绝经期子宫肌瘤的临床研究[J].中国临床药理学杂志,2016,32(11):987-989.
[8] 张俊,李霞,段丽君. 低剂量米非司酮治疗子宫肌瘤的疗效观察[J].中华肿瘤防治杂志,2015,22(22):239-241.
[9] 谢江燕,侯小钰,李娅,等. 米非司酮对子宫肌瘤患者术后激素水平和复发的影响[J].医学临床研究,2015,32(11):2210-2212.
[10] Patel A, Malik M, Britten J, et al. Mifepristone inhibits extracellular matrix formation in uterine leiomyoma[J].Fertil Steril,2016,105(4):1102-1110.
[11] Shen Q, Hua Y, Jiang W, et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis[J].Fertil Steril,2013,100(6):1722-1726.
[12] 王惠. 米非司酮对子宫肌瘤组织内雌和孕激素受体及其表皮生长因子受体的影响分析[J].中华肿瘤防治杂志,2015,22(11):19-20.
[13] 周应芳. 子宫肌瘤药物治疗之评价[J].实用妇产科杂志,2016,32(3):180-182.
(本文编辑:邓丽萍) [收稿日期] 2017-04-21